# Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19

> **NCT04551911** · PHASE2 · COMPLETED · sponsor: **OPKO Health, Inc.** · enrollment: 171 (actual)

## Conditions studied

- COVID-19
- Coronavirus
- SARS-CoV2 Infection

## Interventions

- **DRUG:** Rayaldee
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04551911
- **Lead sponsor:** OPKO Health, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-02
- **Primary completion:** 2021-10-08
- **Final completion:** 2021-10-08
- **Target enrollment:** 171 (ACTUAL)
- **Last updated:** 2024-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04551911

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04551911, "Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04551911. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*